Sign in

    Medicine Azad

    Research Analyst at B Riley

    No confirmed public professional profile or analyst record for Medicine Azad at B. Riley Securities or comparable financial databases could be located. There is no verifiable information regarding their role, company coverage, performance statistics, or professional credentials. It is possible that no such individual holds or has held an analyst or research position with B. Riley under this name.

    Medicine Azad's questions to IMMUNIC (IMUX) leadership

    Medicine Azad's questions to IMMUNIC (IMUX) leadership • Q2 2024

    Question

    Asked about the competitive landscape in light of failures in the BTK inhibitor class and the potential for vidofludimus to leapfrog them. Also inquired about the next steps for a Phase III trial following a positive CALLIPER readout, including the target population.

    Answer

    The recent disappointments in the BTK inhibitor class have opened doors and created an opportunity for vidofludimus as a differentiated alternative. The company is already planning a single Phase III trial for progressive MS, which would likely focus on the non-relapsing secondary progressive population due to the high unmet need, contingent on the strength of the CALLIPER data and overall partnership strategy.

    Ask Fintool Equity Research AI